Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide for Severe Hepatic Veno-Occlusive Disease
NCT00358501Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jul 2006
- Primary completion
- Sep 2008
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label trial of defibrotide in hepatic veno-occlusive disease (HVOD) (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Survival at Day+100 Following Hematopoietic Stem Cell Transplant and Complete Response by Day+100 Post Hematopoietic Stem Cell Transplant. Started Jul 2006; status: completed.
02
Drugs
defibrotide
03
Conditions
hepatic veno-occlusive disease (HVOD)
Beyond the preview
Go deeper on NCT00358501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00358501.